Layoffs hit private gene therapy startups, migraine biotech Satsuma as industry squeeze doesn’t let up
Two small gene therapy makers and a biotech working on an investigational migraine drug have let employees go. The moves add to a broader year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
